THS should begin to ... climb ... as acquisition is completed.
The former name is technically overbought but offers reasons to expect it to grow, while the latter should benefit from the Covid-19 vaccines.
The charts of the recreational vehicle maker seem to paint a developing positive picture.
Despite a holiday drop off looming, we still have movement in bitcoin-related names, the Robinhood folks keep going, and check out ContextLogic's offering.
Dealmaking is going strong and looks set to continue as mental health becomes a key investment theme going forward.
A standard filing has led to an investing opportunity in this electric vehicle name.
I am staying away from this name for now, despite the Alexion acquisition and vaccine promise.
BioXcel Therapeutics and Avadel Pharmaceuticals would make good additions to the portfolios of larger drug companies.
The weaker action this week is exactly what the market needs to keep running into the holidays.
As the DoorDash IPO and Thursday's Airbnb offering get all the eyes, I'm watching special purpose acquisition companies, and here's why.